AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Wiskott-Aldrich Syndrome

Recent research efforts aimed at curing Wiskott-Aldrich Syndrome.

Last updated

Wiskott-Aldrich Syndrome

Overview

Wiskott-Aldrich syndrome (WAS) is a rare, inherited disorder caused by harmful variants in the WAS gene on the X chromosome. It therefore primarily affects boys and causes unusually small, low-number platelets, eczema, recurrent or severe infections, autoimmune disease, and an increased risk of lymphoma. The missing or impaired Wiskott-Aldrich syndrome protein (WASP) disrupts the internal scaffolding that immune cells and platelets need to function normally. GeneReviews: WAS-Related Disorders

Severity varies widely, but untreated classic WAS can be life-threatening because of bleeding, infection, autoimmunity, and cancer risk; a large international natural-history study summarized in GeneReviews reported survival of 78% at age 15 and 65% at age 30 among affected individuals before definitive treatment. Supportive care includes immunoglobulin replacement, preventive and prompt antimicrobial treatment, eczema care, and carefully selected platelet transfusions. Allogeneic hematopoietic stem-cell transplantation (HSCT)—replacement of blood-forming stem cells using a donor—remains a potentially curative standard option, while gene therapy is now an approved curative-intent alternative for a defined group of patients without a suitable matched related donor. GeneReviews: WAS-Related Disorders

Scope of Recent Research (2020–present)

Research since 2020 has been highly active and unusually consequential for such a rare disease: the field has moved from long-term follow-up of early lentiviral gene-therapy studies to regulatory approval of a one-time autologous stem-cell gene therapy. The central questions are now how durably gene-corrected cells restore platelet and immune function, how to minimize chemotherapy-related toxicity and insertion-related cancer risk, and whether precise gene editing can eventually provide more physiologic correction than gene addition. FDA approval announcement FDA Summary Basis for Regulatory Action

Major Breakthroughs and Emerging Therapies

The major breakthrough was the approval of Waskyra (etuvetidigene autotemcel) by the U.S. Food and Drug Administration on December 9, 2025, followed by European Union authorization on January 9, 2026. Waskyra is an ex vivo therapy: clinicians collect a patient’s own CD34+ blood-forming stem and progenitor cells, add a functional copy of the WAS gene using a lentiviral vector outside the body, give conditioning chemotherapy to make marrow space, and reinfuse the corrected cells. It is approved for patients aged six months or older with a WAS mutation when HSCT is appropriate but no suitable HLA-matched related donor is available. FDA approval announcement EMA Waskyra overview

This approval rests on long-term evidence that lentiviral gene addition can produce stable, multi-lineage engraftment and persistent WASP expression. In the original European phase I/II program, the 2022 long-term report found durable corrected-cell engraftment with a median follow-up of 7.6 years and no serious treatment-associated adverse events in the interim analysis, although some autoimmune and platelet abnormalities persisted in individual patients. Long-term lentiviral gene-therapy follow-up A separate U.S. phase I/II study of five patients reported sustained gene marking, reduced infections, eczema, and serious bleeding, while also showing that stronger gene marking in stem-cell-derived colonies was associated with better platelet and myeloid recovery. U.S. phase I/II outcomes

The pooled regulatory dataset for Waskyra included 27 males with severe WAS from two open-label studies and expanded-access programs. FDA reported that severe infections fell from 2.00 to 0.16 events per person-year during the principal pre- versus post-treatment comparison, while moderate or severe bleeding fell from 2.00 to 0.80 events per person-year in the first year after treatment; benefit appeared sustained in longer follow-up. FDA Summary Basis for Regulatory Action These results establish gene addition as a clinically available, disease-modifying approach that addresses the underlying genetic defect rather than only managing symptoms. FDA approval announcement

Gene editing remains experimental but is advancing quickly. A 2020 study used CRISPR-Cas9 and an AAV6 DNA donor to insert a corrective WAS sequence at the native gene location in patient-derived hematopoietic stem and progenitor cells; it reported correction in up to 60% of these cells, restoration of WASP-dependent functions, and persistence of edited cells after transplantation into immunodeficient mice. CRISPR correction of human hematopoietic stem cells A 2024 study instead inserted a corrective WAS sequence into intron 1, a noncoding segment of the gene, restoring WASP expression and WASP-dependent function in patient T cells while preserving multilineage differentiation of edited CD34+ cells in laboratory and mouse experiments. Targeted gene integration study

A further emerging strategy combines CRISPR-Cas9 editing of autologous CD34+ cells with an AAV-delivered, codon-optimized WAS gene template. The European Medicines Agency granted this approach orphan-drug designation in August 2024, which supports development incentives but does not establish that the therapy is authorized, safe, or effective in people. EMA orphan designation for CRISPR/AAV WAS therapy

Clinical Trials and Experimental Approaches

The foundational European lentiviral study, NCT01515462, was a phase I/II study of hematopoietic stem/progenitor-cell gene therapy for severe WAS. Its long-term findings, later incorporated into the Waskyra development program, showed stable engraftment and sustained clinical benefit in treated patients; the trial’s registry includes protocol and statistical-analysis documentation for continued follow-up. NCT01515462 trial record Long-term lentiviral gene-therapy follow-up

In the United States, Boston Children’s Hospital led the completed phase I/II NCT01410825 pilot study, sponsored by David A. Williams. Five patients received autologous CD34+ cells transduced with a self-inactivating lentiviral vector; all were alive and well at a median 7.6-year follow-up in the 2023 publication, with improvements in infections, eczema, and bleeding but variable platelet recovery and autoimmune flares in some patients. NCT01410825 trial record U.S. phase I/II outcomes

The cryopreserved-cell formulation study NCT03837483 was sponsored by Fondazione Telethon and listed as active but not recruiting in its September 2025 registry update. Together with the earlier European study and expanded-access programs, it contributed to the evidence base evaluated for Waskyra approval. NCT03837483 trial record FDA Summary Basis for Regulatory Action

Methodologies and Scientific Approaches

Most curative research uses autologous hematopoietic stem and progenitor cells because these cells can regenerate immune cells, platelets, and other blood lineages for years after reinfusion. In lentiviral gene addition, scientists measure engraftment through vector-copy number, WASP expression across blood-cell types, platelet counts, T-cell function, infection and bleeding rates, and viral-vector integration sites to detect potentially dangerous clonal expansion. FDA Summary Basis for Regulatory Action Long-term lentiviral gene-therapy follow-up

Gene-editing studies use patient-derived CD34+ cells, T and B cells, colony-forming assays, deep sequencing for intended and unintended DNA changes, and transplantation into immunodeficient mice to test whether edited long-term stem cells can establish durable multi-lineage blood production. CRISPR-Cas9 is delivered as a ribonucleoprotein complex by electroporation, while AAV6 commonly supplies the repair template needed for targeted DNA insertion. CRISPR correction of human hematopoietic stem cells Targeted gene integration study

Leading Institutions and Funding

The San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) in Milan and its nonprofit sponsor, Fondazione Telethon, have been central to the development, clinical translation, and regulatory approval of Waskyra. Fondazione Telethon’s 2024 report states that it had invested €161 million in SR-TIGET activities since 1996 and lists a €15.6 million investment figure for the institute’s 2024 activities; the report also recorded 33 patients with WAS treated through Telethon-developed gene therapies as of July 31, 2025. Fondazione Telethon 2024 social report

Other major contributors include Boston Children’s Hospital, Harvard Medical School, the U.S. National Institutes of Health, the National Cancer Institute, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and collaborating centers in North America and Europe. The U.S. phase I/II study received support through NIH and National Heart, Lung, and Blood Institute programs, including the Gene Therapy Resource Program and the Production Assistance for Cellular Therapy program. U.S. phase I/II outcomes

Strengths, Limitations, and Challenges

The strongest evidence now supports lentiviral autologous stem-cell gene therapy as a curative-intent option that avoids the donor search, graft rejection, and graft-versus-host disease associated with allogeneic transplantation. Its advantages are especially important for patients who need definitive treatment but lack a suitable matched related donor. FDA approval announcement However, the evidence base remains small, single-arm, and concentrated at specialist centers, which makes direct comparisons with modern transplantation outcomes uncertain. FDA Summary Basis for Regulatory Action

Important limitations remain. Patients still require conditioning chemotherapy, and early post-treatment vulnerability contributes to infections, low blood counts, catheter complications, and other toxicities. Platelet counts and autoimmune control are not fully normalized in every patient, and integrating lentiviral vectors carry a theoretical risk of insertional mutagenesis, meaning that an insertion near a cancer-associated gene could help drive abnormal cell growth. FDA therefore required a long-term observational safety study, with 15 years of follow-up, to assess secondary malignancies and other delayed risks. FDA Summary Basis for Regulatory Action Gene editing could theoretically preserve normal gene regulation and avoid random vector insertion, but it must still prove durable stem-cell correction, manufacturing consistency, and freedom from off-target or unintended on-target DNA changes in human trials. CRISPR correction of human hematopoietic stem cells Targeted gene integration study

Outlook and Future Directions

As of August 8, 2026, WAS is no longer a disease for which curative therapy is only theoretical: HSCT and, for eligible patients without a suitable matched related donor, approved autologous lentiviral gene therapy provide curative-intent options. The milestones to watch are long-term Waskyra safety and durability data, broader real-world access beyond highly specialized centers, better platelet and autoimmune recovery, less toxic conditioning regimens, and the first human trials of precisely edited autologous stem cells. EMA Waskyra overview EMA orphan designation for CRISPR/AAV WAS therapy

References

Don't see your disease? Request a report